Weight loss pills may fight inflammation linked to cancer

NCT ID NCT05756764

Ongoing Knowledge-focused Sponsor: Louisiana State University Health Sciences Center in New Orleans Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study looks at how losing weight with medications like semaglutide (Wegovy) or tirzepatide (Mounjaro) changes inflammatory cells and fats in the blood. Researchers will measure weight loss, immune cells called MDSCs, and markers like C-reactive protein in 30 adults with obesity. The goal is to understand if weight loss can reduce chronic inflammation that might lead to cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide, Phentermine-Topiramate, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion
What this could lead to: If successful, this study could reveal how weight loss from common medications reduces inflammation, potentially lowering cancer risk.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply to everyone. It measures markers, not actual cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias Inflammation metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO

New Orleans, Louisiana, 70112, United States
Ochsner Health System - Biospecimen

New Orleans, Louisiana, 70121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.